Page last updated: 2024-12-06
nanofin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
nanofin: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 68843 |
| CHEMBL ID | 2104431 |
| SCHEMBL ID | 25816 |
| MeSH ID | M0052556 |
Synonyms (69)
| Synonym |
|---|
| BB 0254893 |
| nanophin |
| nsc-7513 |
| nanofin |
| nanophine |
| naniopinum |
| 504-03-0 |
| lupetidine |
| piperidine,6-dimethyl- |
| wln: t6mtj b1 f1 |
| nsc7513 |
| nanophyn |
| 2,6-lupetidine |
| lupetidin |
| 2,6-dimethylpiperidine |
| piperidine, 2,6-dimethyl- |
| nanofine [inn-french] |
| einecs 207-981-6 |
| nanofina [inn-spanish] |
| brn 0079827 |
| nanofin [inn] |
| nanofinum [inn-latin] |
| nsc 63890 |
| nsc-63890 |
| nsc63890 |
| STK386773 |
| AKOS000118813 |
| naniopine |
| pharmakon1600-01301019 |
| nsc-760379 |
| nsc760379 |
| 2,6-dimethyl-piperidine |
| 5-20-04-00180 (beilstein handbook reference) |
| nanofine |
| nanofinum |
| unii-329i5805bp |
| nanofina |
| 329i5805bp , |
| FT-0648872 |
| FT-0647456 |
| PS-3668 |
| AB02692 |
| CHEMBL2104431 |
| S4992 |
| CCG-213660 |
| AB01326529-02 |
| AM81283 |
| AKOS016038932 |
| SCHEMBL25816 |
| AB76289 |
| CS-4799 |
| 2,6-dimethyl piperidine |
| DTXSID8048527 |
| mfcd00005986 |
| STR03569 |
| HY-B1191 |
| AB01326529_03 |
| J-507521 |
| F2190-0336 |
| SR-01000944275-1 |
| sr-01000944275 |
| NCGC00263473-02 |
| Q4596811 |
| F10355 |
| BRD-A21276153-001-01-1 |
| HMS3886E09 |
| (2r,6r)-2,6-dimethylpiperidine;hydrochloride |
| EN300-19581 |
| Z104474330 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 29.69
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.69) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||